Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $51.5 million.

  • Pharmaceuticals' Total Liabilities rose 12182189.35% to $51.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $51.5 million, marking a year-over-year increase of 12182189.35%. This contributed to the annual value of $51.8 million for FY2024, which is 140.89% up from last year.
  • Pharmaceuticals' Total Liabilities amounted to $51.5 million in Q2 2025, which was up 12182189.35% from $48891.0 recorded in Q1 2025.
  • Pharmaceuticals' 5-year Total Liabilities high stood at $51.8 million for Q4 2024, and its period low was $24031.0 during Q2 2023.
  • Over the past 5 years, Pharmaceuticals' median Total Liabilities value was $30.3 million (recorded in 2021), while the average stood at $28.5 million.
  • Within the past 5 years, the most significant YoY rise in Pharmaceuticals' Total Liabilities was 12182189.35% (2025), while the steepest drop was 9988.51% (2025).
  • Quarter analysis of 5 years shows Pharmaceuticals' Total Liabilities stood at $30.3 million in 2021, then fell by 3.42% to $29.3 million in 2022, then soared by 74.4% to $51.1 million in 2023, then grew by 1.41% to $51.8 million in 2024, then fell by 0.6% to $51.5 million in 2025.
  • Its last three reported values are $51.5 million in Q2 2025, $48891.0 for Q1 2025, and $51.8 million during Q4 2024.